First Patient Dosed in Phase IIb iPREDICT Trial for CD8 ImmunoPET

ImaginAb Inc. announced that the first patient has been dosed at the Macquarie University Hospital in Sydney, Australia as part of its Phase IIb iPREDICT clinical trial. The Phase IIb iPREDICT trial is a part of the company’s clinical development to support marketing approval for CD8 ImmunoPET. iPREDICT is being conducted globally in the US, Australia, and Europe.

The Phase IIb trial aims to assess predictive performance with its primary objective to evaluate the performance of CD8 ImmunoPET positron emission tomography/computed tomography (PET/CT) for predicting patient response to immuno-oncology therapy targeting Melanoma, Merkel Call, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, and other selected solid tumors.

The Olivia Newton John Cancer Research Institute in Melbourne, which is also manufacturing doses for the iPREDICT trial in Australia, delivered the first clinical dose to the Macquarie University Hospital for use by Dr. Alison Zhang in the iPREDICT trial.

“We are delighted to have reached this important clinical development milestone for ImaginAb as we move one step closer to our goal of helping to transform cancer care for patients,” said Ian Wilson, Chief Executive Officer of ImaginAb. “We are actively enrolling the iPREDICT trial over 22 clinical sites across the US, Australia and Europe and would like to thank our local sponsor/CRO, Accelagen, who played a key role in the achievement of this milestone by facilitating smooth communication with our investigators and the sites across the two time zones.”